Sanofi Pasteur MSD

Latest clinical program signals indexed for Sanofi Pasteur MSD.

1. MET55 — Phase 3

   Jun 8, 2026
   Clinical update →

2. MEQ00074 — Phase 3

   Jun 8, 2026
   Clinical update →

3. CYD32 — Phase 3

   Jun 8, 2026
   Clinical update →

4. IPV26 — Phase 2

   Jun 8, 2026
   Clinical update →

5. MEQ00089 — Phase 3

   Jun 8, 2026
   Clinical update →

6. MEQ00073 — Phase 3

   Jun 8, 2026
   Clinical update →

7. Tolebrutinib — Phase 3

   Jun 8, 2026
   Clinical update →

8. Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell — Approved

   Jun 8, 2026
   Clinical update →

1. 2023-508177-85-00

   MEQ00089

   Phase 3 · active · small_molecule

   Healthy volunteers (Meningococcal infection)

   CTIS ↗
2. 2023-510145-25-00

   MEQ00073

   Phase 3 · active · small_molecule

   Meningococcal infection

   CTIS ↗
3. NCT00071279

   SR34006 (idraparinux sodium) Injection

   Phase 3 · completed · small_molecule

   Pulmonary Embolism

   CT.gov ↗
4. NCT00077792

   Enoxaparin sodium (XRP4563)

   Phase 3 · completed · small_molecule

   Myocardial Infarction

   CT.gov ↗
5. NCT00093275

   HP184

   Phase 2 · completed · small_molecule

   Spinal Cord Injury

   CT.gov ↗
6. NCT00130403

   risedronate sodium

   Approved · completed · small_molecule

   Osteoporosis, Postmenopausal

   CT.gov ↗
7. NCT00174655

   Doxorubicine + docetaxel sequential

   Phase 3 · completed · small_molecule

   Breast Neoplasms

   CT.gov ↗
8. NCT00312377

   Docetaxel

   Phase 3 · completed · small_molecule

   Non-small Cell Lung Cancer

   CT.gov ↗
9. NCT00314132

   ChimeriVax-JE, Japanese Encephalitis vaccine

   Phase 3 · completed · mab

   Encephalitis

   CT.gov ↗
10. NCT00347061

    afuzosin

    Phase 3 · completed · small_molecule

    Benign Prostatic Hyperplasia

    CT.gov ↗
11. NCT00348881

    DTaP-HB-PRP~T combined vaccine

    Phase 3 · completed · mab

    Diphtheria

    CT.gov ↗
12. NCT00364351

    Vandetanib

    Phase 3 · completed · small_molecule

    Non Small Cell Lung Cancer

    CT.gov ↗
13. NCT00404924

    ZD6474 (vandetanib)

    Phase 3 · completed · small_molecule

    Non-Small-Cell Lung Carcinoma

    CT.gov ↗
14. NCT00405418

    Insulin Glargine

    Approved · completed · small_molecule

    Diabetes Mellitus, Type 2

    CT.gov ↗
15. NCT00447161

    Bacillus Clausii Multi ATB Resist

    Approved · completed · small_molecule

    Diarrhea, Infantile

    CT.gov ↗
16. NCT00478972

    Rimonabant

    Phase 3 · terminated · small_molecule

    Obesity

    CT.gov ↗
17. NCT00534833

    DTaP-HB-PRP~T vaccine

    Phase 3 · completed · mab

    Diphtheria

    CT.gov ↗
18. NCT00561470

    Placebo

    Phase 3 · completed · small_molecule

    Colorectal Neoplasms

    CT.gov ↗
19. NCT00565448

    docetaxel

    Phase 2 · completed · small_molecule

    Nasopharyngeal Neoplasms

    CT.gov ↗
20. NCT00604058

    Inactivated Poliomyelitis vaccine (IMOVAX)

    Phase 2 · completed · mab

    Poliomyelitis

    CT.gov ↗
21. NCT00607087

    Insulin glulisine

    Approved · completed · small_molecule

    Diabetes Mellitus, Type 1

    CT.gov ↗
22. NCT00622648

    Enoxaparin

    Approved · completed · small_molecule

    Acute Illness

    CT.gov ↗
23. NCT00637819

    Leflunomide

    Phase 2 · completed · small_molecule

    Systemic Lupus Eythematosus (SLE)

    CT.gov ↗
24. NCT00690937

    Enteric coated sevelamer

    Phase 2 · completed · small_molecule

    Hypercholesterolemia

    CT.gov ↗
25. NCT00712673

    Lixisenatide (AVE0010)

    Approved · completed · small_molecule

    Diabetes Mellitus, Type 2

    CT.gov ↗
26. NCT00714597

    Semuloparin sodium

    Phase 3 · terminated · small_molecule

    Venous Thromboembolism

    CT.gov ↗
27. NCT00735644

    Japanese encephalitis vaccine

    Phase 3 · completed · mab

    Japanese Encephalitis

    CT.gov ↗
28. NCT00741897

    Fexofenadine

    Approved · completed · small_molecule

    Rhinitis, Allergic, Perennial

    CT.gov ↗
29. NCT00782041

    Oxaliplatin

    Phase 2 · terminated · small_molecule

    Uterine Neoplasms

    CT.gov ↗
30. NCT00851903

    Insulin Glargine

    Approved · completed · small_molecule

    Diabetes Mellitus, Type 2

    CT.gov ↗
31. NCT00866658

    Lixisenatide (AVE0010)

    Approved · completed · small_molecule

    Diabetes Mellitus, Type 2

    CT.gov ↗
32. NCT00885157

    IPV26

    Phase 2 · completed · mab

    Poliomyelitis

    CT.gov ↗
33. NCT00950534

    INSULIN GLARGINE (HOE901)

    Approved · terminated · small_molecule

    Diabetes Mellitus, Type 2

    CT.gov ↗
34. NCT00982137

    Live attenuated Japanese encephalitis virus; Yellow fever virus

    Phase 2 · completed · mab

    Japanese Encephalitis

    CT.gov ↗
35. NCT01021150

    ombrabulin (AVE8062)

    Phase 1 · completed · small_molecule

    Neoplasms, Malignant

    CT.gov ↗
36. NCT01045304

    Iniparib

    Phase 2 · completed · small_molecule

    Breast Cancer, Metastatic

    CT.gov ↗
37. NCT01147250

    Lixisenatide (AVE0010)

    Phase 3 · completed · small_molecule

    Acute Coronary Syndrome

    CT.gov ↗
38. NCT01254279

    CABAZITAXEL

    Phase 3 · completed · small_molecule

    Prostate Cancer Metastatic

    CT.gov ↗
39. NCT01254422

    CYD32

    Phase 3 · completed · mab

    Dengue Fever

    CT.gov ↗
40. NCT01298323

    Vandetanib

    Phase 3 · completed · small_molecule

    Locally Advanced or Metastatic Medullary Thyroid Cancer

    CT.gov ↗
41. NCT01306721

    fexofenadine HCL (M016455)

    Phase 3 · completed · small_molecule

    Rhinitis Seasonal

    CT.gov ↗
42. NCT01396512

    Live attenuated Japanese encephalitis chimeric virus vaccine

    Phase 3 · completed · mab

    Japanese Encephalitis

    CT.gov ↗
43. NCT01410890

    alglucosidase alfa

    Approved · completed · mab

    Pompe Disease

    CT.gov ↗
44. NCT01551069

    hydroxychloroquine (Z0188)

    Phase 3 · completed · small_molecule

    Cutaneous Lupus Erythematosus-Systemic Lupus Erythematosus

    CT.gov ↗
45. NCT01597596

    alglucosidase alfa

    Approved · terminated · mab

    Pompe Disease (Infantile-Onset)

    CT.gov ↗
46. NCT01622062

    PVRV

    Phase 3 · completed · mab

    Rabies

    CT.gov ↗
47. NCT01663402

    Alirocumab

    Phase 3 · completed · small_molecule

    Atherosclerotic Cardiovascular Disease

    CT.gov ↗
48. NCT01764997

    Sarilumab

    Phase 3 · terminated · small_molecule

    Rheumatoid Arthritis

    CT.gov ↗
49. NCT01930357

    Purified Vero Rabies Vaccine Serum Free (VRVg)

    Phase 2 · completed · mab

    Rabies

    CT.gov ↗
50. NCT01940965

    lixisenatide AVE0010

    Phase 3 · completed · small_molecule

    Type 2 Diabetes Mellitus

    CT.gov ↗
51. NCT01949675

    Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell

    Approved · completed · mab

    Cholera

    CT.gov ↗
52. NCT02004691

    placebo (saline)

    Phase 3 · completed · small_molecule

    Sphingomyelin Lipidosis

    CT.gov ↗
53. NCT02134028

    Dupilumab

    Approved · active · small_molecule

    Asthma

    CT.gov ↗
54. NCT02404558

    sarilumab SAR153191 (REGN88)

    Phase 1 · completed · small_molecule

    Rheumatoid Arthritis

    CT.gov ↗
55. NCT02428491

    Hexaxim®

    Phase 3 · completed · mab

    Diphtheria

    CT.gov ↗
56. NCT02437890

    ALX-0061

    Phase 2 · completed · mab

    Lupus Erythematosus, Systemic

    CT.gov ↗
57. NCT02497612

    Ferroquine SSR97193

    Phase 2 · terminated · small_molecule

    Plasmodium Falciparum Infection

    CT.gov ↗
58. NCT02715726

    Alirocumab

    Phase 3 · completed · small_molecule

    Hypercholesterolemia

    CT.gov ↗
59. NCT02752412

    Insulin glargine/Lixisenatide (HOE901/AVE0010)

    Phase 3 · completed · small_molecule

    Type 2 Diabetes Mellitus

    CT.gov ↗
60. NCT02941367

    Lixisenatide (AVE0010)

    Approved · completed · small_molecule

    Diabetes Mellitus, Type 2

    CT.gov ↗
61. NCT02992418

    CYD Dengue Vaccine

    Phase 3 · terminated · mab

    Dengue Fever

    CT.gov ↗
62. NCT03093480

    rFVIIIFc

    Approved · completed · mab

    Hemophilia A With Inhibitors

    CT.gov ↗
63. NCT03099213

    RAMIPRIL HOE498

    Approved · completed · small_molecule

    Coronary Artery Disease

    CT.gov ↗
64. NCT03190369

    Placebo

    Phase 3 · completed · small_molecule

    Osteoarthritis

    CT.gov ↗
65. NCT03205163

    Advate (Low Dose)

    Phase 2 · completed · mab

    Hemophilia A

    CT.gov ↗
66. NCT03319667

    Isatuximab SAR650984

    Phase 3 · active · small_molecule

    Plasma Cell Myeloma

    CT.gov ↗
67. NCT03417245

    fitusiran

    Phase 3 · completed · small_molecule

    Hemophilia A

    CT.gov ↗
68. NCT03546907

    SAR440340

    Phase 2 · completed · small_molecule

    Chronic Obstructive Pulmonary Disease

    CT.gov ↗
69. NCT04009681

    THOR-707

    Phase 2 · terminated · small_molecule

    Metastasis

    CT.gov ↗
70. NCT04059484

    Amcenestrant

    Phase 2 · terminated · small_molecule

    Breast Cancer Metastatic

    CT.gov ↗
71. NCT04143061

    MET55

    Phase 3 · completed · mab

    Meningococcal Immunization

    CT.gov ↗
72. NCT04411641

    Tolebrutinib

    Phase 3 · completed · small_molecule

    Non-relapsing Secondary Progressive Multiple Sclerosis

    CT.gov ↗
73. NCT04705051

    Venglustat GZ402671

    Phase 3 · terminated · small_molecule

    Congenital Cystic Kidney Disease

    CT.gov ↗
74. NCT04913220

    THOR-707

    Phase 2 · terminated · small_molecule

    Malignant Melanoma

    CT.gov ↗
75. NCT05097287

    Dupilumab

    Approved · active · small_molecule

    Asthma

    CT.gov ↗
76. NCT05588843

    SAR443122

    Phase 2 · active · small_molecule

    Colitis Ulcerative

    CT.gov ↗
77. NCT05704049

    Isatuximab

    Phase 2 · active · small_molecule

    Relapsed/Refractory Multiple Myeloma

    CT.gov ↗
78. NCT05720455

    Fexofenadine HCL and pseudoephedrine HCL

    Approved · completed · small_molecule

    Rhinitis Allergic

    CT.gov ↗
79. NCT05849922

    SAR442970

    Phase 2 · completed · small_molecule

    Hidradenitis Suppurativa

    CT.gov ↗
80. NCT05897424

    SAR447537

    Phase 2 · active · small_molecule

    Alpha 1-Antitrypsin Deficiency

    CT.gov ↗
81. NCT06228586

    MEQ00074

    Phase 3 · completed · mab

    Meningococcal Infection

    CT.gov ↗
82. NCT06392477

    SAR448501

    Phase 1 · active · small_molecule

    B-cell Non Hodgkin Lymphoma

    CT.gov ↗
83. NCT06637631

    SAR441566

    Phase 2 · active · small_molecule

    Crohn's Disease

    CT.gov ↗
84. NCT06676319

    Lunsekimig

    Phase 2 · active · small_molecule

    Asthma

    CT.gov ↗
85. NCT06824181

    PCV21 vaccine

    Phase 3 · active · mab

    Pneumococcal Immunization

    CT.gov ↗
86. NCT06838000

    PCV21

    Phase 3 · active · mab

    Pneumococcal Infections

    CT.gov ↗
87. NCT07088068

    Teplizumab

    Phase 3 · active · small_molecule

    Type 1 Diabetes Mellitus

    CT.gov ↗